Savara Pharmaceuticals Inc., of Austin, Texas, said it closed a $10 million bridge financing round to support the development of Aerovanc, the first inhaled antibiotic being developed to address the growing number of methicillin-resistant Staphylococcus aureus lung infections in people with cystic fibrosis (CF).